TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect
Yasuji Yamamoto(Kobe University), Tadafumi Terada(Taiho Pharmaceutical (Japan))
Cited by 31
Related Papers
Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-FDG-PET: A Multicenter Study
|Journal of Alzheimer s Disease|2015|55